What type of study are you interested in?

Acne

We are evaluating a new prospective generic equivalent of 0.04% Retin-A Micro(R) Gel for the treatment of facial acne. Participants will receive the study medication, 0.04% Retin-A Micro(R) Gel, or a placebo over a 12-week period.

Inclusion Criteria
-	Moderate to severe facial acne
-	General good health
-	Willing to refrain from the use of all other topical acne medications or antibiotics during the study treatment period
-	If a you are a facial cosmetic user, be willing to use only non-comedogenic facial cosmetics during the study treatment period
-	If a you are a sunscreen user, be willing to use only the sunscreen provided by Therapeutics
Exclusion Criteria
-	Pregnant, nursing, or planning a pregnancy
-	Allergy or hypersensitivity to tretinoin
-	Active cystic acne with more than 2 facial nodules
-	Use of systemic retionoid treatment within six months prior to study initiation
-	Start or change in oral contraceptives 3 months prior to study initiation or planned to change during study
-	Significant history of alcohol or drug abuse
-	Participation in any clinical research study during the 30 day period preceding study initiation or plans to participate in another study concurrently
-	Participation in a clinical study for acne within 4 months preceding study initiation
For more details, please contact our recruitment department at 619-512-DERM (3376)

Have you lost your eyelashes due to chemotherapy?

Therapeutics is conducting a research study of an investigational drug called bimatoprost 0.03% to evaluate eyelash loss. If you have recently completed chemotherapy and have lost eyelashes due to treatment, this may be a study of interest to you.

Inclusion Criteria
-	Male or female,18 years of age or older
-	Eyelash loss due to chemotherapy
-	Completion of chemotherapy 4-12 weeks before entry into study
-	No evidence of metastases and no anticipation of further chemotherapy during the course of the study
-	Satisfy other study entry requirements (as provided by study site staff)

For more information, please call our recruitment department direct at 858-279-SKIN (7546)

 

Atopic Keratoconjunctivitis

Therapeutics has a unique opportunity for individuals afflcted with atopic keratoconjunctivitis (AKC), an ocular condition that affects many with atopic disease.

We are studying the efficacy of Cyclosporine Ophthalmic Solution in patients with a clinical diagnosis of AKC. Participants will receive the investigational study medication (or placebo) for three months followed by a nine month "open label" period, a phase where all patients will receive the active investigational study medication

Inclusion Criteria
-	12 years of age or older
-	Corrected visual acuity of 20/800 or better in both eyes
-	Diagnosis of atopic dermatitis & AKC
-	General good health
-	Use or have used steroids to treat AKC
Exclusion Criteria
-	Pregnant, nursing or planning a pregnancy
-	Use of contacts during study
-	Active ocular disease or a history of inflammatory corneal ulcers not related to AKC
-	Enrolled in a research study of an investigational drug or device

All study-related care will be provided at no cost. All study-related visits are at no cost. Compensation is provided for your time and travel.

For more details, please contact our recruitment department at 858-571-6800 x130.

 

Chronic Use of Topical Steroids?

-Study on how blood hormones are affected by long-term steroid use.

Inclusion Criteria
-	Have over 2% of body surface area affected by a chronic skin condition (eczema/psoriasis, etc.)
-	Using topical steroids for at least 3 months for the treatment of any dermatological disease
-	Must be using topical steroids regularly; at least once per day, on average 15 days per month
Exclusion Criteria
-	Pregnant or planning a pregnancy during study period
-	Steroids use (oral, injectable, inhaled, etc.) other than topical steroids
-	Using systemic treatment for skin disease (e.g. Enbrel, Humira, Remicade, Methotrexate, Cyclosporine, etc.)
-	No inhaled steroids for asthma or COPD for the past 3 months (Pulmicort, Flovent, Aerolid, Asmacort, Quar, Advair)

Call our recruitment department for more details. No health insurance is required and your confidentiality is always maintained.

619-512-DERM

Non-Healing Leg Wounds or Sores: Venous Leg Ulcers

Venous ulcers are wounds that are thought to occur due to improper functioning of valves in the veins, usually of the legs. Leg ulcers can be emotionally distressing and painful, and often require months or years to heal.

Therapeutics is conducting a sixteen-week clinical research study to assess the effectiveness of Dermagraft, a tissue-engineered dermal replacement, in the healing of venous leg ulcers. Dermagraft is FDA approved to treat diabetic foot ulcers.

Participants will be examined by a board certified podiatrist and treated with Dermagraft together with multi-layer compression bandaging therapy or with the conventional treatment of multi-layer compression therapy alone. All examinations, dressings and supplies are free of charge, no insurance is required, and compensation is provided for time and travel.

Inclusion Criteria
-	18 years of age or older
-	Three or fewer venous leg ulcers located between the knee and ankle
-	Current episode of ulceration for at least 1 month but less than 24 months
-	Female patients of childbearing potential must be willing to use acceptable methods of contraception
Exclusion Criteria
-	Ulcers caused by a medical condition other than venous insufficiency
-	Acute or chronic bacterial, viral, or fungal diseases that may interfere with wound healing
-	Malignant disease (other than superficial carcinomas of the skin) not in remission for 5 or more years
-	History of radiation at the ulcer site
-	History of AIDS, HIV, active auto-immune or immune diseases or any other medical condition in the opinion of the physician that would make the patient an inappropriate candidate for this wound healing study
-	Previous participation in any Dermagraft trial or recent treatment with tissue engineered materials

If you are interested in participating, please contact us at info@therapeuticsresearch.com or by calling 858-279-SKIN (7546) or 858-571-6800 x130.

 

Seeking Eczema Relief?

Are you seeking relief from red, scaly, cracked and inflamed skin? Have you been diagnosed with atopic dermatitis (also known as eczema)? If you are suffering from this condition, we may have a clinical research trial for you.

Inclusion Criteria
-	18 years of age or older
-	Clinical diagnosis of atopic dermatitis
-	Generally healthy
-	At least one eczema lesion on the body that is not on the hands, feet or genitalia
Exclusion Criteria
-	Pregnant, nursing or planning a pregnancy
-	Any underlying disease or medical condition that in the physician's opinion would confound the study, put the patient at risk, or interfere with the subject's participation
-	History of urinary stones within the last five years or current signs or symptoms of stones.
-	Planned excessive exposure to UV light, whether natural or artificial, during the course of the study

Call our recruitment department for more details or to schedule an appointment.  No health insurance is required and your confidentiality is always maintained. Call us at 858-279-SKIN (7546) or 858-571-6800 x130.

Psoriasis Study Opportunities

We have several interesting opportunities for patients with psoriasis, many offering long term care. If you have psoriasis, you should contact us to learn more. Call us at (858) 279-SKIN (7546) or email us at psoriasis@therapeuticsresearch.com

Study 1

Open-Label trial to evaluate the efficacy of two investigational treatment regimens involving calcitriol and clobetasol propionate in the treatment of moderate plaque psoriasis.

Inclusion Criteria:

• In general good health 18-80 years of age
• Moderate plaque psoriasis (3%-10% of body surface area)

Exclusion Criteria:

• Pregnant, planning a pregnancy or nursing
• Psoriasis only involving the scalp, face, groin, or other areas of the body where adjacent skin surfaces chafe or rub together
• Intake of more than 2000 IU/day (50mcg) of vitamin D and/or more than 1000 mg/day of calcium
• Non-plaque type psoriasis

Study 2

Therapeutics is studying the safety and effectiveness of an investigational medication and is seeking individuals with moderate to severe psoriasis. To participate, you must be 18-65 years of age, weigh less than 265 lbs., and be eligible for systemic psoriasis treatments.

Inclusion Criteria:

• Male or female, 18-65 years of age
• Women of childbearing potential and all men must agree to use adequate birth control measures. Men must agree not to donate sperm during the study
• Diagnosis of plaque psoriasis at least 6 months prior to receiving the study medication
• Plaque psoriasis covering at least 10% of total body surface area at the time of screening and at the time of receiving the study drug
• Two psoriasis plaques suitable for repeat biopsy and photography
• Candidate for phototherapy or systemic treatment of psoriasis
• Agree to avoid prolonged sun exposure and avoid use of tanning booths or other ultraviolet light sources

Exclusion Criteria:

• Pregnant, nursing, or planning a pregnancy
• Non-plaque forms of psoriasis (erythrodermic, guttate, or pustular) or drug-induced psoriasis
• Substance abuse problem within the last 12 months
• Phototherapy or systemic medications that could affect psoriasis within 4 weeks of administration of study drug
• Topical medications or treatment that could affect psoriasis (corticosteroids, tar, anthralin, calcipotriene, topical vitamin D derivatives, retinoids, tazarotene, methoxsalen, trimethyl psoralens) within 2 weeks of administration of study drug
• Use of any agent directly targeted to IL-12, IL-17, or IL-23, including but not limited to ustekinumab, ABT-874, and AIN457
• Use of natalizumab, efalizumab, or agents that deplete B or T cells (rituximab, alemtuzumab, or visilzumab, within 12 months of screening
• Use of systemic immunosupressants (methotrexate, azathioprine, cyclosporine, 6-thigoguanine, mercaptopurine, mycophenolate mofetil, hydroxyrea, or tacrolimus) within 4 weeks of administration of study agent
• History of chronic or recurrent infectious disease or infection
• History of significant muscle disease, cardiomyopathy, mycarditis, or malignancy
• Unstable cardiovascular disease in the last 3 months or a cardiac hospitalization in the last 6 months
• History of lymphoproliferative disease
• Major illness or hospitalization within 1 month prior to receiving the study drug, major surgery within 12 weeks of screening
• Organ transplant (with the exception of corneal transplant) within 3 months of receiving study medication
• History of any clinically significant medical illness or disorder that in the physician's opinion would confound the study, put the patient at risk, or interfere with the subject's participation
• Use of any experimental therapy or new investigational agent within 30 days of receiving the study medication

Call our recruitment department for more details. Your confidentiality is always maintained. 858-279-SKIN or 858-571-6800 x130

Study 3

Clinical trial for topical psoriasis medication; an open label study

Inclusion Criteria:

• Men or women 18-75 years of age
• Mild to moderate chronic plaque-type psoriasis
• In general good health

Exclusion Criteria:

• Pregnant, planning a pregnancy, or nursing
• Non-melanoma skin malignancy in area to be treated within one year of study participation
• Melanoma within the last 5 years prior to study participation
• Currently enrolled in a study for an investigational drug or device

Call our recruitment department for more details. No insurance is required and your confidentiality is always maintained.

858-279-SKIN (7546) or 858-571-6800 x130

 

Diabetic Foot Ulcers

When you have diabetes, taking good care of your skin is very important. As your disease progresses, you will need to pay even more attention to your feet as a number of complications can arise, like diabetic foot ulcers.

Therapeutics Clinical Research is currently enrolling a clinical research trial of a medical food for people with diabetic foot ulcers. If you're 18 years of age or older and would consider taking part in a study of an investigational therapy, we invite you to participate. Qualified participants will receive study-related medical evaluations and therapy at no cost, plus compensation for time and travel. No health insurance is required. For more information and to schedule a free evaluation, please call us at (858) 279-7546.

Do You Have Hand Eczema?

Are you seeking relief from red, dry, cracked and inflamed skin on your hands? Have you been diagnosed with chronic hand eczema, also known as hand dermatitis? If you are suffering from this distressing disease, we may have a clinical research trial for you.

Therapeutics Clinical Research is evaluating the efficacy of Alitretinoin in the treatment of severe, chronic hand eczema. If you are 18-75 years of age and have had hand eczema for at least six months, we invite you to participate. Qualified participants will receive all study-related examinations and study medication at no cost plus compensation for time and travel. No health insurance is required and you confidentiality is always maintained.

Call us at (858) 279-7546 to schedule a free evaluation.